About DVI

December 28,  2015
first country in South America to authorize marketing for dengue vaccine

Following the Mexican government’s approval of Dengvaxia® on December 11 and the Philippines's on December 22 for people aged 9 -45 years living in dengue endemic areas.

What We Do


The Dengue Vaccine Initiative’s work builds on the capabilities of the consortium members and DVI partners to lay the groundwork for dengue vaccine introduction.  Each of the consortium members, whose specialties can be found in the next section, is focusing on projects that utilize their expertise and connections to further the cause of a dengue vaccine.

DVI carries out its work under three Objectives, each with a comprehensive set of Activities: 

Objective 1: Develop sound evidence for decision-making regarding the introduction of dengue vaccines


  1. Prospective dengue surveillance and healthcare utilization studies to estimate disease burden
  2. Cost-of-illness studies
  3. Serological surveys
  4. Mathematical modeling to project vaccine impact
  5. Surveys of private demand for dengue vaccine
  6. Analysis of financing options for dengue vaccine introduction
  7. Dissemination of field study methods and results
  8. Flow cytometry-base neutralization testing of the PDVI samples

Objective 2: Conduct policy and access-related activities to create an enabling environment at the national, regional, and global levels for the introduction of dengue vaccines


  1. Development of dengue vaccine country introduction cases and plans
  2. Development of global investment case for dengue vaccines
  3. Development of global dengue vaccine introduction guidelines
  4. Development of background documentation for review by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization
  5. Convening meetings of the Regional Dengue Prevention Boards
  6. Development and dissemination of dengue informational and advocacy materials
  7. Provision of technical support and training to national regulatory authorities (NRAs) for the evaluation of dengue vaccine trial protocols and applications for vaccine licensure
  8. Facilitation of WHO’s dengue vaccine activities
  9. Development of guidelines for long-term evaluation of dengue vaccines
  10. Development of guidance documents for evaluation of second-generation dengue vaccines

Objective 3:  Enable decision-making for countries interested in early adoption of a dengue vaccine


  1. Development of sets of Points for Consideration for first adopters of dengue vaccines
  2. Management of a coordinating center for Phase 4
  3. Incorporation of mathematical modeling of vaccine impact into Phase 4
  4. Preparation of country-specific demand forecasting and financing options for first adopter countries
  5. Development and dissemination of informational materials to educate the global health community, including dengue endemic countries
  6. Facilitation of technical collaboration and information sharing among national regulatory authorities in countries interested in early adoption of a dengue vaccine